Does AmeriHealth Caritas require prior authorization for J2265?

AmeriHealth Caritas lists J2265 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Fidelis Care require prior authorization for J2265?

Fidelis Care lists J2265 on Fidelis Care CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect HCPCS J2265?

There are 3 tracked policy changes affecting HCPCS J2265, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J2265?

Payers that have issued tracked updates for HCPCS J2265 include: Aetna.

How do I get notified when HCPCS J2265 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J2265. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS J2265?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

J2265 Insurance Policy Changes

HCPCS J2265 is officially defined as "Injection, minocycline hydrochloride, 1 mg." HCPCS J2265 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J2265 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 2, 2026Medium impact
Huntington's Disease (CPB 0614, reviewed 2026-09-24)
Aetna considers these Huntington's disease services experimental, investigational or unproven: functional MRI and PET imaging for monitoring progression, putaminal magnetic resonance spectroscopy for diagnosis, circulating interleukin and other blood, saliva and CSF biomarker tests, deep brain stimulation, electroconvulsive therapy, fetal striatal and stem cell transplantation, and HTT-lowering gene therapy. The CPT and HCPCS codes for these services are listed as not covered for the indications listed, and ICD-10 codes G10 and Z13.858 are listed as not covered for those indications. Deep brain stimulation for Huntington's disease should currently be considered investigational.
Aetna · Identified Aug 15, 2026Medium impact
Huntington's Disease (CPB 0614, reviewed 2026-02-25)
Aetna considers several biomarker and imaging services for Huntington's disease experimental, investigational, or unproven because their effectiveness has not been established. These include functional neuroimaging such as MRI for monitoring progression or predicting the onset of pre-manifest disease, PET imaging for evaluating progression, putaminal magnetic resonance spectroscopy for diagnosis, and circulating interleukin levels, along with neurofilament light chain, tau, salivary total huntingtin and other listed biomarkers. Aetna also considers the listed treatments experimental, investigational, or unproven, including gene therapy with HTT-lowering therapies, stem cell and neural graft transplantation, fetal striatal transplantation, deep brain stimulation, electro-convulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, and wearable or portable digital sensors for clinical management.
Aetna · Identified Aug 14, 2026Medium impact
Acute Ischemic Stroke Treatments (CPB 0789, reviewed 2025-11-19)
Endovascular therapy with a retrievable stent is medically necessary for acute ischemic stroke with occlusion of the middle cerebral artery trunk or its branches, or the internal carotid artery, when salvageable tissue is shown on imaging and retrieval is performed within 12 hours after stroke onset. Intra-arterial infusion of spasmolytics such as papaverine, or calcium-channel blockers such as nicardipine, into intracranial arteries is medically necessary only for medically refractory symptomatic delayed cerebral ischemia (cerebral vasospasm) after aneurysmal subarachnoid hemorrhage, and is experimental, investigational, or unproven for all other indications. Acute stenting with concomitant tirofiban, cerebrolysin, defibrinogen therapy, erythropoietin, hypothermia, transcranial ultrasound such as the CLOTBUST-HF device, sphenopalatine ganglion stimulation, statins, and vagus nerve stimulation for myocardial atrophy after AIS are experimental, investigational, or unproven, along with several other listed therapies.

Watch J2265

Get one email when a payer policy names J2265, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

See every payer rule for J2265

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J2265 in one place.

See every payer rule

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Huntington's Disease (CPB 0614, reviewed 2026-09-24)

Huntington's Disease (CPB 0614, reviewed 2026-02-25)

Acute Ischemic Stroke Treatments (CPB 0789, reviewed 2025-11-19)

Prior authorization required